# Mineralys Therapeutics Inc. (MLYS) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.99, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Mineralys Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.6×**. The shares trade at 2.6× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -23.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 37.4%**. Earnings per share rose 37.4%.

## Financial health
- **Current ratio: 43.76** (quick 43.76). Current assets cover the next year's liabilities 43.76 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Mineralys Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Mineralys Therapeutics Inc.; the consensus is strong_buy, with an average price target of $45.22 (+183% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -61.9%** (YTD -57.2%, 3-mo -39.7%). The shares are down 61.9% over twelve months including dividends.
- **From 52-week high: -66.4%** (4.2% above the low). Trading 66% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 24**. An RSI of 24 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.31** (volatility 63%). Beta of 1.31 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MLYS · Page: https://foliofundamentals.com/stocks/mlys

Not investment advice.